Cost‐effectiveness analysis of sintilimab plus IBI305 versus sorafenib for unresectable hepatic cell carcinoma in China
Cancer Medicine · 2023-07 · 12 (14) · 14871-14880
DOI: 10.1002/cam4.5724 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 11.07.2023. Verfasst von Zhe Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Hunan Province.
Abstract (Originalsprache)
Background
Sintilimab combined with IBI305 treatment regimen had potential clinical benefits than sorafenib in the first‐line treatment of patients with unresectable hepatic cell carcinoma (HCC). However, whether sintilimab plus IBI305 has economic benefits in China remains unclear.
Methods
From the perspective of Chinese payers, we used the Markov model to simulate patients with HCC receiving treatment with sintilimab plus IBI305 and sorafenib. The transition probability between health states was estimated using the parametric survival model, and the cumulative medical costs and utility of the two treatment methods were estimated. Considering the incremental cost‐effectiveness ratios (ICERs) as the evaluation index, sensitivity analyses were performed to explore the impact of uncertainty on the results.
Results
Compared to sorafenib, sintilimab plus IBI305 generated an additional $17552.17 and 0.33 quality‐adjusted life years, resulting in an ICER of $52817.89. The analysis outcomes were most sensitive to the total cost of sintilimab plus IBI305. With a willingness‐to‐pay threshold of $38,334, sintilimab plus IBI305 showed a 1.28% probability of being cost‐effective. The total cost of sintilimab plus IBI305 should be reduced by at least 31.9% to be accepted by Chinese payers.
Conclusions
Regardless of whether the price of sintilimab plus IBI305 and sorafenib is covered by Medicare, sintilimab plus IBI305 is unlikely to be cost‐effective for first‐line treatment of patients with unresectable HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
ORCID-Profile: Zhuo-Miao Ye, Yu-Kai Tang, Qin Zhou, Xiang-Ping Li
Förderung
- Natural Science Foundation of Hunan Province
Zitieren
APA
Xu, Z., Ye, Z. M., Tang, Y. K., Deng, D. F., Zhou, Q., Fang, M., Zhang, Y. Y., & Li, X. P. (2023). Cost‐effectiveness analysis of sintilimab plus IBI305 versus sorafenib for unresectable hepatic cell carcinoma in China. Cancer Medicine, 12(14), 14871-14880. https://doi.org/10.1002/cam4.5724
Vancouver
Xu Z, Ye ZM, Tang YK, Deng DF, Zhou Q, Fang M, et al. Cost‐effectiveness analysis of sintilimab plus IBI305 versus sorafenib for unresectable hepatic cell carcinoma in China. Cancer Medicine. 2023;12(14):14871-14880. doi:10.1002/cam4.5724
BibTeX
@article{Xu2023,
author = {Xu, Zhe and Ye, Zhuo-Miao and Tang, Yu-Kai and Deng, Dong-Feng and Zhou, Qin and Fang, Man and Zhang, Ying-Ying and Li, Xiang-Ping},
title = {Cost‐effectiveness analysis of sintilimab plus IBI305 versus sorafenib for unresectable hepatic cell carcinoma in China},
journal = {Cancer Medicine},
year = {2023},
volume = {12},
number = {14},
pages = {14871--14880},
doi = {10.1002/cam4.5724}
}
EUVIMED